目的 觀察治咳川貝枇杷滴丸對慢性阻塞性肺病急性加重期患者的療效。方法 將60例慢性阻塞性肺病急性加重期患者隨機分為治療組與對照組各30例，對照組給予規(guī)范化常規(guī)治療，治療組患者在對照組治療基礎(chǔ)上再給予治咳川貝枇杷滴丸，口服或舌下含服，6粒/次，3次/d，10 d為一療程，治療結(jié)束后觀察治療療效。結(jié)果 治療后兩組患者血氣指標及CAT評分均優(yōu)于入院時；且治療組與對照組相比改善更明顯（P＜0.05）；治療組起效時間與對照組相比更短；對照組與治療組顯效率分別為73.3%、80%，兩者差異具有統(tǒng)計學意義（P＜0.05）。結(jié)論 在常規(guī)治療基礎(chǔ)上應(yīng)用治咳川貝枇杷滴丸對慢性阻塞性肺病急性加重期患者血氣分析及臨床癥狀改善更明顯，起效時間更短，顯效率更明顯；能夠更快、更好地緩解慢性阻塞性肺病急性加重期患者的癥狀。

Objective To observe the clinical efficacy of Zhike Chuanbei Pipa Dropping Pill (ZCPDP) on acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 60 patients with acute exacerbation of COPD were randomly divided into treatment (30 cases) and control (30 cases) groups. The patients in the control group were treated with standardized conventional treatment, and the patients in the treatment group were po or sublingually administered with ZCPDP In the control group, after treated as same as the treatment group the patients were administered with ZCPDP six pills once for three times daily, 10 d as one course. The therapeutic efficacy was evaluated in the end of the treatment. Results Indexes of blood gas analysis and CAT in two groups were all improved, especially in the treatment group (P < 0.05). The onset time of treatment group was shorter than that of control group. The significant efficiency of control and treatment groups was 73.3% and 80%, respectively, with the significant difference between the two groups (P < 0.05). Conclusion Combination with ZCPDP on the basis of conventional treatment could improve the result of blood-Qi analysis and the clinical symptoms more obviously, the onset time is more shorter, and the significant efficiency is more remarkable. It could relieve the acute exacerbation of COPD faster and better.